Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences

Biologics: Targets and Therapy

Volumn 2, Issue 2, 2008, Pages 229-252

  Stoll, Matthew L ^a   Gotte, Alisa C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biologics; Juvenile idiopathic arthritis; Rheumatoid arthritis

Indexed keywords

EID: 79956288931     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s2210     Document Type: Review

References (256)

1. No authors listed 2007. Rituxan warning. FDA Consum, 41:3.
2. Abe T, Takeuchi T, Miyasaka N, et al. 2006. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol, 33:37-44.
3. Abrams JR, Lebwohl MG, Guzzo CA, et al. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest, 103:1243-52.
4. Allantaz F, Chaussabel D, Stichweh D, et al. 2007. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med, 204:2131-44.
5. Anderson GM, Nakada MT, DeWitte M. 2004. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol, 4:314-20.
6. Antoni C, Krueger GG, de Vlam K, et al. 2005a. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis, 64:1150-7.
7. Antoni CE, Kavanaugh A, Kirkham B, et al. 2005b. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum, 52:1227-36.
8. Armbrust W, Kamphuis SS, Wolfs TW, et al. 2004. Tuberculosis in a nineyear- old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford), 43:527-9.
9. Askling J, Fored CM, Baecklund E, et al. 2005a. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis, 64:1414-20.
10. Askling J, Fored CM, Brandt L, et al. 2005b. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis, 64:1421-6.
11. Askling J, Fored CM, Brandt L, et al. 2007. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis, 66:1339-44.
12. Baecklund E, Iliadou A, Askling J, et al. 2006. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum, 54:692-701.
13. Baert F, Noman M, Vermeire S, et al. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med, 348:601-8.
14. Bendele AM, Chlipala ES, Scherrer J, et al. 2000. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum, 43:2648-59.
15. Bendtzen K, Geborek P, Svenson M, et al. 2006. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum, 54:3782-9.
16. Bennett CM, Rogers ZR, Kinnamon DD, et al. 2006. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 107:2639-42.
17. Bernatsky S, Hudson M, Suissa S. 2007. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford), 46:1157-60.
18. Biester S, Deuter C, Michels H, et al. 2007. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol, 91:319-24.
19. Billiau AD, Cornillie F, Wouters, C. 2002. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J Rheumatol, 29:1111-4.
20. Bluestone JA, St Clair EW, Turka LA. 2006. CTLA4Ig: bridging the basic immunology with clinical application. Immunity, 24:233-8.
21. Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295:2275-85.
22. Brandt J, Khariouzov A, Listing J, et al. 2003. Six-month results of a doubleblind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum, 48:1667-75.
23. Braun J, Davis J, Dougados M, et al. 2006. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis, 65:316-20.
24. Breedveld FC, Weisman MH, Kavanaugh AF, et al. 2006. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum, 54:26-37.
25. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum, 41:2196-204.
26. [BTS] British Thoracic Society Standards of Care Committee. 2005. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax, 60:800-5.
27. Brown SL, Greene MH, Gershon SK, et al. 2002. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum, 46:3151-8.
28. Brulhart L, Ciurea A, Finckh A, et al. 2006. Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study. Ann Rheum Dis, 65:1255-7.
29. Burgos-Vargas R, Casasola-Vargas J, Gutierrez-Suarez R, et al. 2007. Efficacy, safety, and tolerability of infliximab in juvenile-onset spondyloarthropathies (JO-SpA): results of the three-month, randomized, double-blind, placebo-controlled trial phase [abstract]. Arthritis Rheum, 56(suppl):S319.
30. Burgos-Vargas R, Rudwaleit M, Sieper J. 2002a. The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol, 29:869-74.
31. Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, et al. 2002b. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis, 61:941-2.
32. Calin A, Dijkmans BA, Emery P, et al. 2004. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis, 63:1594-600.
33. Campion GV, Lebsack ME, Lookabaugh J, et al. 1996. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum, 39:1092-101.
34. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. 2005. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum, 52:1766-72.
35. Carswell EA, Old LJ, Kassel RL, et al. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 72:3666-70.
36. Chadha T, Hernandez JE. 2006. Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum, 55:163-6.
37. Cheifetz A, Mayer L. 2005. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med, 72:250-6.
38. Chen J, Liu C. 2006. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol, 33:722-31.
39. Choy EH, Isenberg DA, Garrood T, et al. 2002. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, doubleblind, placebo-controlled, dose-escalation trial. Arthritis Rheum, 46:3143-50.
40. Cohen JD, Bournerias I, Buffard V, et al. 2007. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol, 34:380-5.
41. Cohen S, Hurd E, Cush J, et al. 2002. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 46:614-24.
42. Cohen SB. 2004. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am, 30:365-80, vii
43. Cohen SB, Emery P, Greenwald MW, et al. 2006. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum, 54:2793-806.
44. Cohen SB, Moreland LW, Cush JJ, et al. 2004. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis, 63:1062-8.
45. Crandall WV, Mackner LM. 2003 Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther, 17:75-84.
46. Curtis JR, Patkar N, Xie A, et al. 2007. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum, 56:1125-33.
47. Dass S, Vital EM, Emery P. 2007. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum, 56:2715-18.
48. Davis JC Jr., Van Der Heijde D, Braun J, et al. 2003. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum, 48:3230-6.
49. De Bandt M, Sibilia J, Le Loet X, et al. 2005. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther, 7:R545-51.
50. de Benedetti F, Massa M, Robbioni P, et al. 1991. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum, 34:1158-63.
51. De Marco G, Gerloni V, Pontikaki I, et al. 2007. [Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy.]. Reumatismo, 59:50-6.
52. Dinarello CA. 1996. Biologic basis for interleukin-1 in disease. Blood, 87:2095-147.
53. Dixon W, Silman A. 2006. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Res Ther, 8:111.
54. Dixon WG, Symmons DP, Lunt M, et al. 2007. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum, 56:2896-904.
55. Dixon WG, Watson K, Lunt M, et al. 2006. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum, 54:2368-76.
56. Doran MF, Crowson CS, Pond GR, et al. 2002. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population- based study. Arthritis Rheum, 46:2287-93.
57. Edwards JC, Szczepanski L, Szechinski J, et al. 2004. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med, 350:2572-81.
58. Eisenberg SP, Evans RJ, Arend WP, et al. 1990. Primary structure and functional expression from complementary DNA of a human interleukin- 1 receptor antagonist. Nature, 343:341-6.
59. El-Hallak M, Binstadt BA, Leichtner AM, et al. 2007. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr, 150:376-82.
60. Elliott MJ, Maini RN, Feldmann M, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet, 344:1105-10.
61. Elliott MJ, Woo P, Charles P, et al. 1997. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol, 36:589-93.
62. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. 2006. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum, 54:1390-400.
63. Feige U, Hu YL, Gasser J, et al. 2000. Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci, 57:1457-70.
64. Feldmann M, Brennan FM, Williams RO, et al. 2004. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol, 18:59-80.
65. Ferraro-Peyret C, Coury F, Tebib JG, et al. 2004. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther, 6:R535-43.
66. Ferucci ED, Majka DS, Parrish LA, et al. 2005. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum, 52:239-46.
67. Finckh A, Ciurea A, Brulhart L, et al. 2007. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to antitumor necrosis factor agents. Arthritis Rheum, 56:1417-23.
68. Fishman D, Faulds G, Jeffery R, et al. 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest, 102:1369-76.
69. Fitzgerald AA, Leclercq SA, Yan A, et al. 2005. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum, 52:1794-803.
70. Fleischmann RM, Schechtman J, Bennett R, et al. 2003. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum, 48:927-34.
71. Fleischmann RM, Tesser J, Schiff MH, et al. 2006. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis, 65:1006-12.
72. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. 2007. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritisassociated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol, 34:1146-50.
73. Franklin J, Lunt M, Bunn D, et al. 2006. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis, 65:617-22.
74. Franklin JP, Symmons DP, Silman AJ, 2005. Risk of lymphoma in patients with RA treated with anti-TNFalpha agents. Ann Rheum Dis, 64:657-8.
75. Freim Wahl SG, Folvik MR, Torp SH. 2007. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol, 26:68-73.
76. Furst DE, Cush J, Kaufmann S, et al. 2002. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis, 61 (Suppl 2):ii62-ii63.
77. Furst DE, Schiff MH, Fleischmann RM, et al. 2003. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol, 30:2563-71.
78. Fusconi M, Vannini A, Dall'aglio AC, et al. 2007. Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis. Rheumatol Int, 28:47-9.
79. Gartlehner G, Hansen RA, Jonas BL, et al. 2006. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol, 33:2398-408.
80. Gartlehner G, Hansen RA, Jonas BL, et al. 2008. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol, 27:67-76.
81. Geborek P, Bladstrom A, Turesson C, et al. 2005. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis, 64:699-703.
82. Genovese M, Breedveld FC, Emery P, et al. 2006. TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab [abstract]. Arthritis Rheum, 54 (suppl):S329.
83. Genovese MC, Becker JC, Schiff M, et al. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med, 353:1114-23.
84. Genovese MC, Cohen S, Moreland L, et al. 2004. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum, 50:1412-9.
85. Genovese MC, Mease PJ, Thomson GT, et al. 2007. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol, 34:1040-50.
86. Gensler L, Davis JC Jr. 2006. Recognition and treatment of juvenile-onset spondyloarthritis. Curr Opin Rheumatol, 18:507-11.
87. Gerloni V, Pontikaki I, Gattinara M, et al. 2005. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum, 52:548-53.
88. Goldberg SL, Pecora AL, Alter RS, et al. 2002. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood, 99:1486-8.
89. Gomez-Reino JJ, Carmona L, Valverde VR, et al. 2003. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter activesurveillance report. Arthritis Rheum, 48:2122-7.
90. Gottenberg JE, Guillevin L, Lambotte O, et al. 2005. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis, 64:913-20.
91. Grillo-Lopez AJ, White CA, Varns C, et al. 1999. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol, 26:66-73.
92. Haibel H, Brandt HC, Song IH, et al. 2007. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis, 66:419-21.
93. Hashkes PJ, Laxer RM. 2006. Update on the medical treatment of juvenile idiopathic arthritis. Curr Rheumatol Rep, 8:450-8.
94. Henrickson M, Reiff A. 2004. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol, 31:2055-61.
95. Higashida J, Wun T, Schmidt S, et al. 2005. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol, 32:2109-15.
96. Hopkins SJ, Meager A. 1988. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin Exp Immunol, 73:88-92.
97. Horneff G, Schmeling H, Biedermann T, et al. 2004. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis, 63:1638-44.
98. Huang JL, Chen LC. 1998. Sulphasalazine in the treatment of children with chronic arthritis. Clin Rheumatol, 17:359-63.
99. Ilowite N, Reiff A, Rudge S, et al. 2006. A randomized, multi-center, blinded, placebo-controlled study with an open-label run-in period to evaluate anakinra in polyarticular-course juvenile rheumatoid arthritis [abstract]. Arthritis Rheum, 54(Suppl):S327-28.
100. Ilowite NT, Porras O, Reiff A, et al. 2003. A twelve-week open label safety and efficacy study of anakinra (Kineret) in juvenile rheumatoid arthritis [abstract]. Ann Rheum Dis, 62(suppl 1):87.
101. Imagawa T, Mori M, Takei S, et al. 2006. Efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in patients with polyarticular or oligoarticular onset juvenile idiopathic arthritis [abstract]. Arthritis Rheum, 54(suppl):S168.
102. Irigoyen PI, Olson J, Hom C, et al. 2004. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra [abstract]. Arthritis Rheum, 50(suppl) S437.
103. Isaacs JD, Morgan AW, Strand V. 1999. Combination biologic therapy. Clin Exp Rheumatol, 17:S121-4.
104. Jiang Y, Genant HK, Watt I, et al. 2000. A multicenter, double-blind, doseranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum, 43:1001-9.
105. Jois RN, Masding A, Somerville M, et al. 2007. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience. Rheumatology (Oxford), 46:980-2.
106. Kahn P, Weiss M, Imundo LF, et al. 2006. Favorable response to highdose infliximab for refractory childhood uveitis. Ophthalmology, 113:860-4 e2.
107. Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. 2007. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis, 66:842-3.
108. Kapetanovic MC, Larsson L, Truedsson L, et al. 2006. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther, 8:R131.
109. Katsicas MM, Russo RA. 2005. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol, 23:545-8.
110. Kaur N, Mahl TC. 2007. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci, 52:1481-4.
111. Kavanaugh A, St Clair EW, McCune WJ, et al. 2000. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol, 27:841-50.
112. Kesteman T, Yombi JC, Gigi J, et al. 2007. Listeria infections associated with infliximab: case reports. Clin Rheumatol, 26:2173-5.
113. Keystone EC. 2005. Safety of biologic therapies--an update. J Rheumatol Suppl, 74:8-12.
114. Keystone EC, Kavanaugh AF, Sharp JT, et al. 2004a. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum, 50:1400-11.
115. Keystone EC, Schiff MH, Kremer JM, et al. 2004b. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 50:353-63.
116. Kietz DA, Pepmueller PH, Moore TL. 2002. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis, 61:171-3.
117. Kimby E. 2005. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev, 31:456-73.
118. Kimura Y, Pinho P, Walco G, et al. 2005. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol, 32:935-42.
119. Kinder A, Stephens S, Mortimer N, et al. 2004. Severe herpes zoster after infliximab infusion. Postgrad Med J, 80:26.
120. Klareskog L, van der Heijde D, de Jager JP, et al. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet, 363:675-81.
121. Kneitz C, Wilhelm M, Tony HP. 2004. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol, 33:82-6.
122. Kone-Paut I, Retornaz K, Garnier JM, et al. 2007. Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (Anakinra). Clin Exp Rheumatol, 25:119.
123. Kotter I, Wacker A, Koch S, et al. 2007. Anakinra in patients with treatmentresistant adult-onset still's disease: Four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum, 37:189-97.
124. Kremer JM, Dougados M, Emery P, et al. 2005. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelvemonth results of a phase iib, double-blind, randomized, placebocontrolled trial. Arthritis Rheum, 52:2263-71.
125. Kremer JM, Genant HK, Moreland LW, et al. 2006. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med, 144:865-76.
126. Kremer JM, Westhovens R, Leon M, et al. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med, 349:1907-15.
127. Kroesen S, Widmer AF, Tyndall A, et al. 2003. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford), 42:617-21.
128. Krumrey-Langkammerer M, Hafner R. 2001. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol, 28:2544-7.
129. Kuek A, Hazleman BL, Gaston JH, et al. 2006. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford), 45:1448-9.
130. Kuemmerle-Deschner JB, Horneff G. 2007. Safety and efficacy of once weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatol Int, 28:153-6.
131. Lahdenne P, Vahasalo P, Honkanen V. 2003. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis, 62:245-7.
132. Lan JL, Chou SJ, Chen DY, et al. 2004. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. J Formos Med Assoc, 103:618-23.
133. Leandro MJ, Cambridge G, Ehrenstein MR, et al. 2006. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum, 54:613-20.
134. Leandro MJ, Edwards JC, Cambridge G. 2002. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis, 61:883-8.
135. Lehman TJ. 2007. The future of pediatric rheumatology: Many questions remain. Arthritis Rheum, 56:2815-16.
136. Lepore L, Marchetti F, Facchini S, et al. 2003. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol, 21:276-7.
137. Lequerre T, Quartier P, Rosellini D, et al. 2008. Interleukin-1 receptor antagonist (Anakinra) treatment with patients with systemiconset juvenile idiopathic arthritis or adult onset Still's disease: preliminary experience in France. Ann Rheum Dis, 67:302-8.
138. Linsley PS, Brady W, Urnes M, et al. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med, 174:561-9.
139. Lipsky PE, van der Heijde DM, St Clair EW, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med, 343:1594-602.
140. Listing J, Strangfeld A, Kary S, et al. 2005. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum, 52:3403-12.
141. Lovell D, Ruperto N, Jung L, et al. 2006a. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results [abstract]. Arthritis Rheum, 54(suppl):S329.
142. Lovell DJ. 2006. Update on treatment of arthritis in children: new treatments, new goals. Bull NYU Hosp Jt Dis, 64:72-6.
143. Lovell DJ, Giannini EH, Reiff A, et al. 2000. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med, 342:763-9.
144. Lovell DJ, Reiff A, Jones OY, et al. 2006b. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum, 54:1987-94.
145. Lovell DJ, Ruperto N, Prieur AM, et al. 2006c. assessment of open label co-stimulation blockade with abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA) [abstract]. Arthritis Rheum, 54(Suppl):S326.
146. Lovell DJ, Ruperto N, Prieur AM, et al. 2007. Abatacept treatment of juvenile idiopathic arthritis (JIA): safety report [abstract]. Arthritis Rheum, 56(Suppl):S292.
147. Maini RN, Breedveld FC, Kalden JR, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum, 41:1552-63.
148. Maini RN, Taylor PC, Szechinski J, et al. 2006. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum, 54:2817-29.
149. Manners PJ, Bower C. 2002. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol, 29:1520-30.
150. Mariette X, Salmon D. 2003. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis, 62:791.
151. Marks SD, Patey S, Brogan PA, et al. 2005. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum, 52:3168-74.
152. Marzo-Ortega H, McGonagle D, Jarrett S, et al. 2005. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis, 64:1568-75.
153. Matsubara T, Hasegawa M, Shiraishi M, et al. 2006. A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents. Arthritis Rheum, 54:2314-20.
154. Matteucci P, Magni M, Di Nicola M, et al. 2002. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood, 100:1104-5.
155. Mease PJ, Gladman DD, Ritchlin CT, et al. 2005. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum, 52:3279-89.
156. Mease PJ, Goffe BS, Metz J, et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet, 356:385-90.
157. Minden K, Kiessling U, Listing J, et al. 2000. Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol, 27:2256-63.
158. Mohrbacher A. 2005. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther, 7(Suppl 3):S19-25.
159. Moore J, Ma D, Will R, et al. 2004. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant, 34:241-7.
160. Mor A, Bingham C 3rd, Barisoni L, et al. 2005. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol, 32:740-3.
161. Moreland LW, Alten R, Van den Bosch F, et al. 2002. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum, 46:1470-9.
162. Moreland LW, Baumgartner SW, Schiff MH, et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med, 337:141-7.
163. Moreland LW, Schiff MH, Baumgartner SW, et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med, 130:478-86.
164. Nishimoto N, Hashimoto J, Miyasaka N, et al. 2007. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis, 66:1162-7.
165. Nishimoto N, Yoshizaki K, Miyasaka N, et al. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum, 50:1761-9.
166. Norambuena RX, Mallol J, Rios MG, et al. 2007. Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis. Allergol Immunopathol (Madr), 35:52-6.
167. Ogilvie EM, Fife MS, Thompson SD, et al. 2003. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum, 48:3202-6.
168. Ogilvie EM, Khan A, Hubank M, et al. 2007. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum, 56:1954-65.
169. Parodi E, Nobili B, Perrotta S, et al. 2006. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol, 84:48-53.
170. Pascual V, Allantaz F, Arce E, et al. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med, 201:1479-86.
171. Peek R, Scott-Jupp R, Strike H, et al. 2006. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis, 65:1259.
172. Petty RE, Southwood TR, Manners P, et al. 2004. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol, 31:390-2.
173. Pijpe J, van Imhoff GW, Spijkervet FK, et al. 2005. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum, 52:2740-50.
174. Pincus T, Stein CM. 1997. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol, 15(Suppl 17):S27-38.
175. Pirard D, Arco D, Debrouckere V, et al. 2006. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology, 213:182-6.
176. Popa C, Leandro MJ, Cambridge G, et al. 2007. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford), 46:626-30.
177. Prescott K, Costner M, Cohen S, et al. 2007. Tumor necrosis factor-alpha inhibitor associated ulcerative colitis. Am J Med Sci, 333:137-9.
178. Prince FH, Twilt M, Jansen-Wijngaarden NC, et al. 2007. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis, 66:704-5.
179. Quartier P, Brethon B, Philippet P, et al. 2001. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet, 358:1511-3.
180. Quartier P, Taupin P, Bourdeaut F, et al. 2003. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum, 48:1093-101.
181. Quartuccio L, De Vita S. 2007. Interleukin 1 receptor antagonist therapy-induced thrombocytopenia in adult onset Still's disease. J Rheumatol, 34:892-3.
182. Quinn MA, Conaghan PG, O'Connor PJ, et al. 2005. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 52:27-35.
183. Rajaraman RT, Kimura Y, Li S, et al. 2006. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology, 113:308-14.
184. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. 2007. Autoimmune diseases induced by tnf-targeted therapies: Analysis of 233 cases. Medicine (Baltimore), 86:242-51.
185. Rankin EC, Choy EH, Kassimos D, et al. 1995. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol, 34:334-42.
186. Rao A, Kelly M, Musselman M, et al. 2007. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer, 50:822-5.
187. Reiff A, Takei S, Sadeghi S, et al. 2001. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum, 44:1411-5.
188. Richards JC, Tay-Kearney ML, Murray K, et al. 2005. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Experiment Ophthalmol, 33:461-8.
189. Rigby WF. 2007. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol, 3:227-33.
190. Rooney M, David J, Symons J, et al. 1995. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol, 34:454-60.
191. Ruiz PJ, Masliah E, Doherty TA, et al. 2007. Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis, 66:422-3.
192. Ruperto N, Lovell DJ, Cuttica R, et al. 2007. A randomized, placebocontrolled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum, 56:3096-106.
193. Russo RA, Katsicas MM, Zelazko M. 2002. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol, 20:723-6.
194. Saint Marcoux B, De Bandt M. 2006. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine, 73:710-13.
195. Salliot C, Gossec L, Ruyssen-Witrand A, et al. 2007. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford), 46:327-34.
196. Salomon B, Bluestone JA. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol, 19:225-52.
197. Sampaio-Barros PD, Costallat LT, Bertolo MB, et al. 2000. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol, 29:160-2.
198. Sato K, Tsuchiya M, Saldanha J, et al. 1993. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res, 53:851-6.
199. Saurenmann RK, Levin AV, Rose JB, et al. 2006. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford), 45:982-9.
200. Saxena N, Misra R, Aggarwal A. 2006. Is the enthesitis-related arthritis subtype of juvenile idiopathic arthritis a form of chronic reactive arthritis? Rheumatology (Oxford), 45:1129-32.
201. Schaller J, Kupfer C, Wedgwood RJ. 1969. Iridocyclitis in juvenile rheumatoid arthritis. Pediatrics, 44:92-100.
202. Scheinberg M, Hamerschlak N, Kutner JM, et al. 2006. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol, 24:65-9.
203. Schmeling H, Horneff G. 2004. Infliximab in two patients with juvenile ankylosing spondylitis. Rheumatol Int, 24:173-6.
204. Schmeling H, Horneff G. 2005. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford), 44:1008-11.
205. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. 2007. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum, 56:1754-64.
206. Setoguchi S, Solomon DH, Weinblatt ME, et al. 2006. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum, 54:2757-64.
207. Settas LD, Tsimirikas G, Vosvotekas G, et al. 2007. Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J Clin Rheumatol, 13:219-20.
208. Sicotte NL, Voskuhl RR. 2001. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology, 57:1885-8.
209. Siddiqui MA. 2007. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr Opin Rheumatol, 19:308-13.
210. Smith JA, Thompson DJ, Whitcup SM, et al. 2005. A randomized, placebocontrolled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum, 53:18-23.
211. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. 2008. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet, 371:987-97.
212. Smolen JS, Keystone EC, Emery P, et al. 2007. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis, 66:143-50.
213. Solal-Celigny P. 2006. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res, 30 (Suppl 1):S16-21.
214. St Clair EW, van der Heijde DM, Smolen JS, et al. 2004. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum, 50:3432-43.
215. Steurer M, Clausen J, Gotwald T, et al. 2003. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation, 76:435-6.
216. Tanaka Y, Yamamoto K, Takeuchi T, et al. 2007. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol, 17:191-7.
217. Tanno M, Nakamura I, Kobayashi S, et al. 2006. New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol, 25:929-33.
218. Taylor PC, Steuer A, Gruber J, et al. 2004. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum, 50:1107-16.
219. Thompson RC, Dripps DJ, Eisenberg SP. 1992. Interleukin-1 receptor antagonist (IL-1ra) as a probe and as a treatment for IL-1 mediated disease. Int J Immunopharmacol, 14:475-80.
220. Thonhofer R, Gaugg M, Kriessmayr M, et al. 2005. Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis, 64:1098-9.
221. Todd DJ, Costenbader KH, Weinblatt MT. 2007. Abatacept in the treatment of rheumatoid arthritis. Int J Clin Prac, 61:494-500.
222. Todd DJ, Helfgott SM. 2007. Serum sickness following treatment with rituximab. J Rheumatol, 34:430-3.
223. Tse SM, Burgos-Vargas R, Laxer RM. 2005. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum, 52:2103-8.
224. Tsutsumi Y, Kanamori H, Mori A, et al. 2005. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf, 4:599-608.
225. Tubach F, Ravaud P, Salmon-Ceron D, et al. 2006. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factoralpha antagonists. Clin Infect Dis, 43:e95-100.
226. Turesson C, Riesbeck K. 2004. Septicemia with Staphylococcus aureus, beta-hemolytic streptococci group B and G, and Escherichia coli in a patient with rheumatoid arthritis treated with a recombinant human interleukin 1 receptor antagonist (Anakinra). J Rheumatol, 31:1876.
227. Tynjala P, Lindahl P, Honkanen V, et al. 2007. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis, 66:548-50.
228. van de Putte LB, Atkins C, Malaise M, et al. 2004. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis, 63:508-16.
229. van de Putte LB, Rau R, Breedveld FC, et al. 2003. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis, 62:1168-77.
230. van den Berg WB. 2002. Is there a rationale for combined TNF and IL-1 blocking in arthritis? Clin Exp Rheumatol, 20:S21-5.
231. Van Den Bosch F, Kruithof E, Baeten D, et al. 2002. Randomized doubleblind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum, 46:755-65.
232. van der Heijde D, Da Silva JC, Dougados M, et al. 2006a. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis, 65:1572-7.
233. van der Heijde D, Dijkmans B, Geusens P, et al. 2005. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum, 52:582-91.
234. van der Heijde D, Kivitz A, Schiff MH, et al. 2006b. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 54:2136-46.
235. van Ede A, den Broeder A, Wagenaar M, et al. 2007. Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. J Rheumatol, 34:1590-2.
236. Vasques Godinho FM, Parreira Santos, MJ and Canas da Silva, J 2005. Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis, 64:647-8.
237. Vazquez-Cobian LB, Flynn T, Lehman TJ. 2006. Adalimumab therapy for childhood uveitis. J Pediatr, 149:572-5.
238. Verbsky JW, White AJ. 2004. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol, 31:2071-5.
239. Verschueren K, Van Essche E, Verschueren P, et al. 2007. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol, 26:1969-71.
240. Wang J, Wiley JM, Luddy R, et al. 2005. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr, 146:217-21.
241. Weinblatt M, Comb, B, Covucci A, et al. 2006. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum, 54:2807-16.
242. Weinblatt M, Schiff M, Goldman A, et al. 2007. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis, 66:228-34.
243. Weinblatt ME, Keystone EC, Furst DE, et al. 2003. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum, 48:35-45.
244. Weinblatt ME, Kremer JM, Bankhurst AD, et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med, 340:253-9.
245. Westhovens R, Yocum D, Han J, et al. 2006. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebocontrolled trial. Arthritis Rheum, 54:1075-86.
246. Willems M, Haddad E, Niaudet P, et al. 2006. Rituximab therapy for childhood- onset systemic lupus erythematosus. J Pediatr, 148:623-27.
247. Wolfe F, Caplan L, Michaud K. 2006. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum, 54:628-34.
248. Wolfe F, Michaud K. 2004. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum, 50:1740-51.
249. Wolfe F, Michaud K. 2007a. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum, 56:2886-95.
250. Wolfe F, Michaud K. 2007b. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum, 56:1433-9.
251. Woo P, Wilkinson N, Prieur AM, et al. 2005. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther, 7:R1281-8.
252. Yokota S, Imagawa T, Mori M, et al. 2008. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet, 371:998-1006.
253. Yokota S, Miyamae T, Imagawa T, et al. 2005. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic- onset juvenile idiopathic arthritis. Arthritis Rheum, 52:818-25.
254. Zhou H. 2005. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol, 45:490-7.
255. Zink A, Strangfeld A, Schneider M, et al. 2006. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum, 54:3399-407.
256. Zwerina J, Hayer S, Tohidast-Akrad M, et al. 2004. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum, 50:277-90.